Company
Epigenomics AG
Headquarters: Berlin, Germany
Employees: 32
CEO: Mr. Gregory Hamilton
Market Cap
€6.2 Million
EUR as of Feb. 1, 2023
US$6.7 Million
Epigenomics AG Categories
Germany Healthcare Diagnostics & ResearchGermany Healthcare Germany Diagnostics & Research
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $207.62 B |
| Danaher | $171.89 B |
| Siemens Healthineers AG | $66.05 B |
| DexCom, Inc. | $46.50 B |
| IDEXX Laboratories, Inc. | $44.72 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Top 1-year algo backtest: +298.72%
$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Epigenomics AG has the following listings and related stock indices.
Stock: FSX: ECX wb_incandescent
Stock: XETR: ECX wb_incandescent
Stock: OTC: EPGNF wb_incandescent
Stock: OTC: EPGNY wb_incandescent